You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昆藥集團(600422.SH)擬出資5000萬元共同設立維立公司 持股佔比6.2112%
格隆匯 09-29 17:55

格隆匯9月29日丨昆藥集團(600422.SH)公佈,公司擬與上海國鴻智言創業投資合夥企業(有限合夥)等其他五方投資者共同投資南京維立志博生物科技有限公司(以下簡稱“維立公司”)。

本輪投資者擬投資1.3億元人民幣,其中認繳本次標的公司新增的註冊資本185.5062萬元人民幣,其餘1.28億元人民幣計入標的公司資本公積。標的公司註冊資本由963.2051萬元人民幣增加至1148.7113萬元人民幣。

本輪投資中,公司擬投資5000萬元,認繳標的公司本輪投資新增部分註冊資本,投資完成後,公司擬持有標的公司6.2112%的股權。

同時,雙方進一步約定,上述人民幣5000萬元的增資款項,其中人民幣2000萬元將作為公司聯合領投方的出資款,剩餘人民幣3000萬元應在滿足雙方就成立合資公司事項簽署相關合資經營合同及企業章程的先決條件後再予以出資。

維立公司是一家臨牀階段的生物製藥公司,由資深留美抗體藥物研發團隊創立,專注於具有自主知識產權的治療腫瘤和其他重大疾病的抗體新藥研發,特別是腫瘤免疫治療面臨的問題和挑戰。

抗腫瘤領域作為公司聚焦和重點佈局的核心治療領域之一,維立公司作為一家專注於腫瘤免疫治療抗體新藥研發的醫藥創新企業,雙方本次在股權及後續潛在合作方面達成協議,是公司佈局腫瘤治療領域的又一重要舉措,對公司具有重要的戰略意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account